Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
30 July 2021Website:
http://www.maxcyte.comNext earnings report:
12 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 22 Nov 2024 21:02:42 GMTDividend
Analysts recommendations
Institutional Ownership
MXCT Latest News
Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects
ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences.
MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024.
MaxCyte, Inc.'s stock performance has been disappointing since its 2021 IPO, despite positive business developments and a 34% revenue growth. The company faces high capital requirements for modest revenue gains, but has a substantial cash reserve to sustain operations. FDA approval of CASGVEY validates MaxCyte's platform, with potential multi-billion dollar opportunities and significant future revenue.
Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology
ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the Virtual Craig-Hallum Capital Group Bioprocessing Conference on Thursday, September 19th at 9:30 am ET.
MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2024 Earnings Call August 6, 2024 4:30 PM ET Company Participants Scott Feinberg - Investor Relations Maher Masoud - President and Chief Executive Officer Doug Swirsky - Chief Financial Officer Conference Call Participants Hannah Hefley - Stephens Julie Simmonds - Panmure Liberum Steven Mah - TD Cowen Matt Larew - William Blair Jack Siedow - Craig-Hallum Capital Group Paul Cuddon - Deutsche Numis Mark Massaro - BTIG Operator Ladies and gentlemen, thank you for standing by. Welcome to MaxCyte Second Quarter Earnings Conference Call.
MaxCyte (MXCT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
- 1(current)
What type of business is MaxCyte?
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
What sector is MaxCyte in?
MaxCyte is in the Healthcare sector
What industry is MaxCyte in?
MaxCyte is in the Medical Devices industry
What country is MaxCyte from?
MaxCyte is headquartered in United States
When did MaxCyte go public?
MaxCyte initial public offering (IPO) was on 30 July 2021
What is MaxCyte website?
https://www.maxcyte.com
Is MaxCyte in the S&P 500?
No, MaxCyte is not included in the S&P 500 index
Is MaxCyte in the NASDAQ 100?
No, MaxCyte is not included in the NASDAQ 100 index
Is MaxCyte in the Dow Jones?
No, MaxCyte is not included in the Dow Jones index
When was MaxCyte the previous earnings report?
No data
When does MaxCyte earnings report?
The next expected earnings date for MaxCyte is 12 March 2025